The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Evolving Strategies for the Management of Hand–Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib
Open accessAbstract
The multitargeted kinase inhibitors (MKIs) sorafenib and sunitinib have shown benefit in patients with renal cell carcinoma, hepatocellular carcinoma (sorafenib), and gastrointestinal stromal tumor (sunitinib). Their efficacy in other malignancies is currently being investigated because of their broad range of activity. The effectiveness of these drugs is somewhat diminished by the development of a variety of toxicities, most notably hand–foot skin reaction (HFSR). Although HFSR does not appear to directly affect survival, it can impact quality of life and lead to MKI dose modification or interruption, potentially limiting the antitumor effect. Currently, no standard guidelines exist for the prevention and management of MKI-associated HFSR. To address this issue, an international, interdisciplinary panel of experts gathered in January 2008 to discuss and evaluate the best-practice management of these reactions. Based on these proceedings, recommendations for the management of HFSR have been provided to offer patients the best possible quality of life while taking these drugs and to optimize the patient benefit associated with MKI therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097 · cited 2×
“servation (RCC) or standard therapies (HCC), leading to the approval of sorafenib in these disease settings; overall survival was also longer in patients with HCC [ 6 , 8, 22].”
BackgroundPatterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G., Judson, I. R., Heinrich, M. C., Morgan, J. A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69446-4 · Cited by 2,607
Angiogenesis: an organizing principle for drug discovery?
Folkman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2115 · Cited by 2,246
Liu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A., Wilkie, D., Wilhelm, S., Lynch, M., & Carter, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1377 · Cited by 1,536
Faivre, S., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., Bello, C., Deprimo, S., Brega, N., Massimini, G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2194 · Cited by 1,164
Self-citationRatain, M. J., Eisen, T., Stadler, W. M., Flaherty, K. T., Kaye, S. B., Rosner, G. L., Gore, M., Desai, A. A., Patnaik, A., Xiong, H. Q., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6723 · Cited by 1,032
Erber, R., Thurnher, A., D. Katsen, A., Groth, G., Kerger, H., Hammes, H., D. Menger, M., Ullrich, A., & Vajkoczy, P. (2004) · The FASEB Journal · doi:10.1096/fj.03-0271fje · Cited by 610
Spector, W. D., Katz, S., Murphy, J. B., & Fulton, J. P. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90004-x · Cited by 565
Cutaneous side-effects of kinase inhibitors and blocking antibodies
Robert, C., Soria, J.-C., Spatz, A., Le Cesne, A., Malka, D., Pautier, P., Wechsler, J., Lhomme, C., Escudier, B., Boige, V., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70243-6 · Cited by 554
Self-citationCommon Terminology Criteria for Adverse Events v3.0 (CTCAE)
(2008) · Principles and Practice of Clinical Trial Medicine · doi:10.1016/b978-0-12-373695-6.00022-3 · Cited by 457
Quality of Life in Patients with Psoriasis: A Systematic Literature Review
de Korte, J., Mombers, F. M. C., Bos, J. D., & Sprangers, M. A. G. (2004) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1046/j.1087-0024.2003.09110.x · Cited by 441
Katz, S., & Akpom, C. A. (1976) · Medical Care · doi:10.1097/00005650-197605001-00018 · Cited by 372
Nagore, E., Insa, A., & Sanmart??n, O. (2000) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200001040-00004 · Cited by 298
Lacouture, M. E., Reilly, L. M., Gerami, P., & Guitart, J. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn389 · Cited by 255
Self-citationKinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma
Ahmad, T., & Eisen, T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040028 · Cited by 244
Bhojani, N., Jeldres, C., Patard, J.-J., Perrotte, P., Suardi, N., Hutterer, G., Patenaude, F., Oudard, S., & Karakiewicz, P. I. (2008) · European Urology · doi:10.1016/j.eururo.2007.11.037 · Cited by 239
Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis
Chu, D., Lacouture, M. E., Fillos, T., & Wu, S. (2008) · Acta Oncologica · doi:10.1080/02841860701765675 · Cited by 197
Self-citationDevelopment and validation of a quality of life instrument for cutaneous diseases
Anderson, R. T., & Rajagopalan, R. (1997) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(97)70210-x · Cited by 193
Self-citationYang, C.-H., Lin, W.-C., Chuang, C.-K., Chang, Y.-C., Pang, S.-T., Lin, Y.-C., Kuo, T.-T., Hsieh, J.-J., & Chang, J. W. C. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08357.x · Cited by 182
Human keratinocytes are a major source of cutaneous platelet-derived growth factor.
Ansel, J. C., Tiesman, J. P., Olerud, J. E., Krueger, J. G., Krane, J. F., Tara, D., Shipley, G. D., Gilbertson, D. M., Usui, M. L., & Hart, C. E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116636 · Cited by 157
Porta, C., Paglino, C., Imarisio, I., & Bonomi, L. (2007) · Clinical and Experimental Medicine · doi:10.1007/s10238-007-0145-8 · Cited by 147
Chren, M., Lasek, R. J., Quinn, L., & Covinsky, K. E. (1997) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12285650 · Cited by 123
Sorafenib and Sunitinib: Novel Targeted Therapies for Renal Cell Cancer
Grandinetti, C. A., & Goldspiel, B. R. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.8.1125 · Cited by 119
Jacobi, U., Waibler, E., Schulze, P., Sehouli, J., Oskay-Özcelik, G., Schmook, T., Sterry, W., & Lademann, J. M. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi204 · Cited by 114
Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib
Rosenbaum, S. E., Wu, S., Newman, M. A., West, D. P., Kuzel, T. M., & Lacouture, M. E. (2008) · Supportive Care in Cancer · doi:10.1007/s00520-008-0409-1 · Cited by 112
Self-citationHagemann, I. S., & Proksch, E. (1996) · Acta Dermato Venereologica · doi:10.2340/0001555576353356 · Cited by 103
Chu, D. T. W., Lacouture, M. E., Weiner, E., & Wu, S. (2009) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2009.n.002 · Cited by 95
Self-citationEpithelial-Stromal Interactions in Basal Cell Cancer: The PDGF System
Pontén, F., Ren, Z.-P., Nistér, M., Westermark, B., & Pontén, J. (1994) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12371787 · Cited by 90
Hair Depigmentation Is a Biological Readout for Pharmacological Inhibition of KIT in Mice and Humans
Moss, K. G., Toner, G. C., Cherrington, J. M., Mendel, D. B., & Laird, A. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.052530 · Cited by 82
The measurement of Instrumental ADL: Content validity and construct validity
Avlund, K., Schultz‐Larsen, K., & Kreiner, S. (1993) · Aging Clinical and Experimental Research · doi:10.1007/bf03324192 · Cited by 66
Sunitinib: A Cause of Bullous Palmoplantar Erythrodysesthesia, Periungual Erythema, and Mucositis
Suwattee, P., Chow, S., Berg, B. C., & Warshaw, E. M. (2008) · Archives of Dermatology · doi:10.1001/archderm.144.1.123 · Cited by 38
Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib
Sergio Bracarda, A., Caserta, C., Sordini, L., Rossi, M., Hamzay, A., & Crinò, L. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm219 · Cited by 38
Thompson, D. S., Greco, F. A., Spigel, D. R., Sosman, J. A., Burkett, E., O’Rourke, T. J., Hart, L., & Hainsworth, J. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.4594 · Cited by 22
Lipton (1995) · Pure Amsterdam UMC · doi:10.1002/1097-0142(19950415)75:8 · Cited by 1
Cited by
Zhu, A. X., Rosmorduc, O., Evans, T. R. J., Ross, P. J., Santoro, A., Carrilho, F. J., Bruix, J., Qin, S., Thuluvath, P. J., Llovet, J. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.7746 · Cited by 576
Abou-Alfa, G. K., Johnson, P., Knox, J. J., Capanu, M., Davidenko, I., Lacava, J., Leung, T., Gansukh, B., & Saltz, L. B. (2010) · JAMA · doi:10.1001/jama.2010.1672 · Cited by 448
Review article: the management of hepatocellular carcinoma
CABRERA, R., & NELSON, D. R. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04200.x · Cited by 222
Metadata
- Authors
- Lacouture, M. E., Wu, S., Robert, C., Atkins, M. B., Kong, H. H., Guitart, J., Garbe, C., Hauschild, A., Puzanov, I., Alexandrescu, D. T., Anderson, R. T., Wood, L., & Dutcher, J. P.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-09-01
- Volume
- 13
- Issue
- 9
- Pages
- 1001-1011
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2100512801
- Cited by
- 337
- References
- 38
- FWCI
- 27.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.